NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
批准号:
10346091
负责人:
DAVID W. GOODRICH
金额:
$4.86万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-05-22 至 2024-04-30
关键词:
AcetatesAffectAndrogen ReceptorAndrogensAutomobile DrivingCell CommunicationClinicalDNA Sequence AlterationDevelopmentDevelopment PlansEpigenetic ProcessGeneticGoalsGrantIn VitroIncidenceMalignant NeoplasmsMalignant neoplasm of prostateMentorsMetastatic Prostate CancerMolecularNeuroendocrine Prostate CancerNeurosecretory SystemsOrganoidsParentsPathway interactionsPatientsPhenotypeProstate AdenocarcinomaProstate Cancer therapyRB1 geneReceptor SignalingRelapseResearchResearch SupportRoleSignal TransductionStudentsTP53 geneTestingTherapeuticTumor Suppressor GenesVariantabirateroneandrogen deprivation therapyandrogen independent prostate cancerandrogen sensitiveanticancer researchcancer cellcareer developmentcastration resistant prostate cancerderepressioneffective therapyimprovedmolecular targeted therapiesnotch proteinnovel strategiespre-doctoralprogramsreceptor expressionresponsetherapy resistanttransdifferentiationtumor microenvironment
中文摘要
摘要
雄激素剥夺疗法(ADT)对转移性前列腺癌(PADC)有效,但所有
患者不可避免地复发,患有去势抵抗性前列腺癌(CRPC)。大多数CRPC仍然依赖于
雄激素受体(AR)信号,但有相当一部分缺乏AR表达,成为AR信号
独立并异常表达神经内分泌谱系标记物(NEPC)。这些NEPC的发生率
随着更多的患者受益于改善的ADT,如苯扎鲁胺和醋酸阿比特龙,变异药物的数量也增加了。
这表明,越来越严格的AR信号封锁正在推动NEPC的发展。NEPC咄咄逼人
而且是致命的,因此反映了一个日益严重的临床问题。有效疗法的开发因有限而受阻
了解相关的分子机制。NEPC显然起源于ARpos CRPC,因为它们共享克隆
起源于两者都有的患者。我们已经确定RB1/Trp53肿瘤的遗传失活
抑制基因协同作用促进ARPOS PADC向NEPC的转化
表观遗传重编程因素。抑制这些重新编程因素会逆转NEPC转换和
恢复ADT敏感性,表明涉及表观遗传变化。我们假设Notch信号
在肿瘤微环境中抑制潜在的NEPC的表观遗传重编程
转分化。这一假设具有临床后果,因为可以想象,这种途径可能是
通过治疗手段延缓或逆转NEPC转化,延长受益ADT的持续时间
部分患者出现临床反应。此管理多样性补充应用程序旨在支持
毛里西奥·弗洛雷斯,博士前学生,将参与家长R01资助的研究项目
研究Notch信号在NEPC转分化中的作用。研究、指导和职业生涯
发展计划提出了三个研究目标:1)确定足以支持的有机培养条件
2)检测Notch信号对体外培养的NEPC转分化的影响;
确定在体外影响NEPC转分化的间质-癌细胞相互作用。的长期目标是
这一多样性补充是为了促进弗洛雷斯先生的癌症研究事业发展和改善前列腺癌
通过促进对谱系可塑性作为获得性机制的机制的理解进行癌症治疗
治疗抵抗力。
英文摘要
Summary
Androgen deprivation therapy (ADT) is effective in treating metastatic prostate adenocarcinoma (PADC), but all
patients inevitably relapse with castrate resistant prostate cancer (CRPC). Most CRPCs remain dependent on
androgen receptor (AR) signaling, but a significant fraction lack AR expression, become AR signaling
independent, and aberrantly express neuroendocrine lineage markers (NEPC). The incidence of these NEPC
variants has increased as more patients benefit from improved ADTs like enzalutamide and abiraterone acetate.
This suggests increasingly stringent AR signaling blockade is driving development of NEPC. NEPC is aggressive
and lethal, thus reflecting a growing clinical problem. Development of effective therapies is hampered by limited
understanding of relevant molecular mechanisms. NEPC clearly arises from ARpos CRPC as they share clonal
origin in patients that harbor both. We have determined that genetic inactivation of the RB1/TRP53 tumor
suppressor genes cooperate to facilitate transformation of ARpos PADC to NEPC through derepression of
epigenetic reprogramming factors. Inhibiting these reprogramming factors reverses NEPC transformation and
restores ADT sensitivity, demonstrating that epigenetic changes are involved. We hypothesize Notch signaling
within the tumor microenvironment suppresses the epigenetic reprogramming underlying NEPC
transdifferentiation. This hypothesis has clinical ramifications as the pathway could conceivably be
manipulated therapeutically to delay or reverse NEPC transformation, extending the duration of beneficial ADT
clinical responses in some patients. This administrative diversity supplement application is proposed to support
Mauricio Flores, a predoctoral student who will be involved in the parent R01 grant supported research program
characterizing the role of NOTCH signaling in NEPC transdifferentiation. The research, mentoring, and career
development plan proposes three research aims: 1) Identify organoid culture conditions sufficient to support
NEPC transdifferentiation in vitro; 2) Test how Notch signaling affects NEPC transdifferentiation in vitro; 3)
Identify stromal-cancer cell interactions that influence NEPC transdifferentiation in vitro. The long-term goal of
this diversity supplement is to facilitate Mr. Flores' cancer research career development and to improve prostate
cancer therapy by advancing mechanistic understanding of lineage plasticity as a mechanism of acquired
therapeutic resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistance
-
批准号:10829724
-
项目类别:
-
资助金额:$8.59万
-
财政年份:2022
-
负责人:DAVID W. GOODRICH
-
依托单位:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
-
批准号:10516537
-
项目类别:
-
资助金额:$105.04万
-
财政年份:2022
-
负责人:DAVID W. GOODRICH
-
依托单位:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
-
批准号:10682495
-
项目类别:
-
资助金额:$102.48万
-
财政年份:2022
-
负责人:DAVID W. GOODRICH
-
依托单位:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
-
批准号:10524127
-
项目类别:
-
资助金额:$5.56万
-
财政年份:2019
-
负责人:DAVID W. GOODRICH
-
依托单位:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
-
批准号:10759015
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2019
-
负责人:DAVID W. GOODRICH
-
依托单位:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
-
批准号:10641672
-
项目类别:
-
资助金额:$62.91万
-
财政年份:2019
-
负责人:DAVID W. GOODRICH
-
依托单位:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
-
批准号:10397535
-
项目类别:
-
资助金额:$10.93万
-
财政年份:2019
-
负责人:DAVID W. GOODRICH
-
依托单位:
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
-
批准号:8587206
-
项目类别:
-
资助金额:$22.16万
-
财政年份:2013
-
负责人:DAVID W. GOODRICH
-
依托单位:
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
-
批准号:8708795
-
项目类别:
-
资助金额:$17.91万
-
财政年份:2013
-
负责人:DAVID W. GOODRICH
-
依托单位:
The Role of Thoc1 in Normal Development and Cancer
-
批准号:7332285
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2007
-
负责人:DAVID W. GOODRICH
-
依托单位:
The Role of Thoc1 in Normal Development and Cancer
-
批准号:7191477
-
项目类别:
-
资助金额:$33.91万
-
财政年份:2007
-
负责人:DAVID W. GOODRICH
-
依托单位:
The Role of Thoc1 in Normal Development and Cancer
-
批准号:7750616
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2007
-
负责人:DAVID W. GOODRICH
-
依托单位:
The Role of Thoc1 in Normal Development and Cancer
-
批准号:7991830
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2007
-
负责人:DAVID W. GOODRICH
-
依托单位:
The Role of Thoc1 in Normal Development and Cancer
-
批准号:7541458
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2007
-
负责人:DAVID W. GOODRICH
-
依托单位:
REGULATION OF RB PROTEIN FUNCTION BY CYCLIN-DEPENDENT
-
批准号:2683644
-
项目类别:
-
资助金额:$21.92万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
REGULATION OF RB PROTEIN FUNCTION BY CYCLIN-DEPENDENT
-
批准号:2390919
-
项目类别:
-
资助金额:$21.78万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
Requirements for Normal Rb Function In Vivo
-
批准号:7895483
-
项目类别:
-
资助金额:$37.64万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
Requirements for Normal Rb Function In Vivo
-
批准号:6541731
-
项目类别:
-
资助金额:$30.83万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
Requirements for Normal Rb Function In Vivo
-
批准号:6769405
-
项目类别:
-
资助金额:$31.56万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
Requirements for Normal Rb Function In Vivo
-
批准号:7094115
-
项目类别:
-
资助金额:$47.66万
-
财政年份:1996
-
负责人:DAVID W. GOODRICH
-
依托单位:
海外基金